DOCSLIB.ORG

Name: Gerald F. Gebhart, Ph.D. Home Address: 450 E. Waterside Drive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Name: Gerald F. Gebhart, Ph.D. Home Address: 450 E. Waterside Drive 1 CURRICULUM VITAE BIOGRAPHICAL Name: Gerald F. Gebhart, Ph.D. Home Address: 450 E. Waterside Drive, #3407 Chicago, IL Home Phone: (312) 450-1242 E-mail Address: [email protected]; [email protected] EDUCATION AND TRAINING UNDERGRADUATE: Dates Attended Institution Degree and Year Major 1963-1967 University of Illinois B.S., 1967 Pharmacy Chicago, IL (with honors) GRADUATE: Dates Attended Institution Degree and Year Major 1967-1969 The University of Iowa M.S., 1969 Pharmacology Iowa City, IA 1969-1971 The University of Iowa Ph.D., 1971 Pharmacology Iowa City, IA Advisor: C.L. Mitchell, Ph.D. POSTGRADUATE: Dates Attended Institution Program Director & Discipline 1971-1973 Center for Research in Neuroscience Neurological Sciences H.H. Jasper, Supervisor Université de Montreal, Canada APPOINTMENTS AND POSITIONS ACADEMIC: Dates Inclusive Institution Title 1973-1977 The Univ. of Iowa Assistant Professor Iowa City, IA Dept. of Pharmacology 1977-1981 The Univ. of Iowa Associate Professor Iowa City, IA Dept. of Pharmacology 1981-2006 The Univ. of Iowa Professor Iowa City, IA Dept. of Pharmacology 1981-1982 Universität Heidelberg, Germany Visiting Scientist Dept. of Physiology Dept. of Physiology 2 1983-1984 The University of Iowa Acting Head Iowa City, IA Dept. of Pharmacology 1996-2006 The University of Iowa Head Iowa City, IA Department of Pharmacology 2006 The University of Iowa Professor Emeritus Iowa City, IA 2006-2016 The University of Pittsburgh Professor School of Medicine Department of Anesthesiology Department of Anesthesiology (Primary Appointment) Pittsburgh, PA 2006-2016 The University of Pittsburgh Professor of Neurobiology, School of Medicine Professor of Pharmacology, Pittsburgh, PA Professor of Medicine/GI (Secondary Appointments) 2006-2016 The University of Pittsburgh Director Pittsburgh Center for Pain Research (PCPR) Pittsburgh, PA 2011-2016 The University of Pittsburg Professor Clinical & Translational Science Institute (Secondary Appointment) 2017-present NorthShore University Health System Senior Clinician Researcher University of Chicago Pritzker School of Medicine Department of Obstetrics and Gynecology, Chicago, IL MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES Year Organization 1972 - 2016 Society for Neuroscience 2004-2007 Program Committee 1975 - present International Association for the Study of Pain 1981-1986 Committee on Research and Ethical Issues 1984-1987 Scientific Program Committee for Vth World Congress 1986-1990 Committee on Ethical Issues 1987-1990 Scientific Program Committee for VIth World Congress 1987-1990 Task Force on Professional Education 1990-1993 Scientific Program Committee for VIIth World Congress, Chair 1993-1996 Scientific Program Committee for VIIIth World Congress 1990-1996 Committee on Honorary Members and Special Lectures 1990-1996 Committee on Research 1990-1996 Committee on Publications 1991-1993 Committee on Financial Aid 3 1996-1999 Committee on Nominations, Chair 2005-2008 President Elect 2006 Strategic Plan Task Force 2007 Bylaws Revision Committee 2007 Committee on Committees Task Force 2007 Meetings Task Force 2008-2010 President 2010-2012 Past President 2011-2012 PAIN Editor in Chief Search Committee 2012 Nominations Committee, Chair 2013-2016 Terminology Task Force 2013 PAIN Editor in Chief Advisory Group 2014 Nominations Committee 2015-2016 Governance Task Force 2017 Nominations Task Force 1976-2016 American Society for Pharmacology and Experimental Therapeutics 1999 Co-organizer, 1st Ray Fuller Symposium, Cellular Mechanisms and Novel Strategies for Pain Control, Indianapolis, IN 1978 - present American Pain Society 1983-1985 Research Committee 1984-1985 Research Committee Chair 1985-1988 Scientific and Professional Ethics Committee 1987-1988 Scientific and Professional Ethics Committee Chair 1989-1990 Scientific and Professional Ethics Committee Co-Chair 1991-1994 Board of Directors (Elected) 1997-1998 President (Elected) 1999-2002 Awards Committee 1999 Awards Committee Chair 1999-2000 Nominating Committee (Elected) 2000-2010 Editor in Chief, The Journal of Pain 2002-2003 Nominating Committee (Elected) 2000-2009 Ethics Committee 2001-2007 Task Force: Decade of Pain Control and Research 2001-2003 Scientific Program Committee 2002 Scientific Program Committee Chair 2004–2010 Publications Committee 2004-2005 Industry Relations Task Force 2006 APS Journal Publisher Task Force 2006-2013 Future Leaders in Pain Research Grants Review Committee 2006-2007 Scientific Program Committee Task Force 2007-2009 Nominating Committee (Elected) 2011-2012 Ad hoc Committee: Management Company Review 2011-2014 Nominating Committee (Elected) 2016-2017 Nominating Committee, Chair 2017 Chief Executive Officer Replacement Task Force 1983-2016 American Physiological Society 1995-2016 American Gastroenterological Association 2010-2016 Mentor, Foundation for Anesthesia Education and Research 4 HONORS Year 1971-1973 Medical Research Council of Canada Fellow (Université de Montreal) 1981-1982 Alexander von Humboldt Research Fellow (Universität Heidelberg) 1989-1994 Bristol-Myers Squibb Co. Unrestricted Pain Research Award 1993-2003 NIH MERIT award (R37 DA02879) 1994 Fredrick W.L. Kerr Research Award, American Pain Society 1996-1999 President Elect, President, and Past President, American Pain Society 1998 John J. Bonica Award and Lecture, Eastern Pain Society, New York, NY 1998 M2 Teacher of the Year, UI College of Medicine 1999 Benjamin G. Covino Lecture, Harvard Medical School, Boston, MA 2000 John J. Bonica Award and Lecture, American Society of Regional Anesthesia, Orlando, FL 2003 Distinguished Service Award, American Pain Society 2004 Purdue Pharma Prize for Pain Research 2004 Gunn-Loke Lecture, University of Washington, Seattle, WA 2004 Highly Cited Researcher (Neuroscience) – Thomson-ISI 2005 Masters Award in Gastroenterology, American Gastroenterological Association 2006 Founders Award, American Academy of Pain Medicine 2006-2012 President Elect, President, and Past President, International Association for the Study of Pain 2012 Patrick Wall Award and Lecture, British Pain Society, Liverpool, UK 2014 University Iowa Carver College of Medicine Distinguished Alumnus Award for Achievement 2014 Tripuraneni Oration, American Neurogastroenterology & Motility Society, Baltimore, MD 2015 30th Annual Bonica Lecture, University of Washington, Seattle, WA 2016 Honorary Member (elected), International Association for the Study of Pain 2018 G.F. Gebhart Journal of Pain Early Career Investigator Award established by the American Pain Society PUBLICATIONS 1. Gebhart, G.F., Plaa, G.L. and Mitchell, C.L. The effects of ethanol alone and in combination with phenobarbital, chlorpromazine or chlordiazepoxide. Toxicol. Appl. Pharmacol. 15: 405-414, 1969. 2. Gebhart, G.F. and Mitchell, C.L. Further studies on the development of tolerance to the analgesic effect of morphine: The role played by the cylinder in the hot plate testing procedure. Arch. Int. Pharmacodyn. Ther. 191: 96-103, 1971. 3. Gebhart, G.F., Sherman, A.D. and Mitchell, C.L. The influence of learning on morphine analgesia and tolerance development in rats tested on the hot plate. Psychopharmacologia 22: 295-304, 1971. 4. Gebhart, G.F. and Mitchell, C.L. The relative contributions of the testing cylinder and the heated plate in the hot plate procedure to the development of tolerance to morphine in rats. Eur. J. Pharmacol. 18: 56-63, 1972. 5 5. Gebhart, G.F., Sherman, A.D. and Mitchell, C.L. The influence of stress on tolerance development to morphine in rats tested on the hot plate. Arch. Int. Pharmacodyn. Ther. 197: 328-337, 1972. 6. Gebhart, G.F. and Mitchell C.L. The effect of adrenalectomy on morphine analgesia and tolerance development in rats. Eur. J. Pharmacol. 18: 37-43, 1972. 7. Gebhart, G.F. and Mitchell, C.L. Strain differences in the analgesic response to morphine as measured on the hot plate. Arch. Int. Pharmacodyn. Ther. 201: 128-135, 1973. 8. Sherman, A.D. and Gebhart, G.F. Regional levels of GABA and glutamate in mouse brain following exposure to either pain and/or morphine. Neuropharmacol. 13: 673-675, 1974. 9. Sherman, A.D. and Gebhart, G.F. Pain-induced alteration of glutamate in periaqueductal central gray and its reversal by morphine. Life Sci. 15: 1781-1789, 1974. 10. Sherman, A.D. and Gebhart, G.F. An evaluation of the analgesia induced by morphine and gamma-hydroxybutyrate. Arch. Int. Pharmacodyn. Ther. 213: 199, 1975. 11. Lewis, V.A. and Gebhart, G.F. A simple electrolytic method for cutting small diameter stainless steel tubing. J. Appl. Physiol. 40: 278, 1976. 12. Sherman, A.D. and Gebhart, G.F. Morphine and pain: Effects on aspartate, GABA and glutamate in four discrete area of mouse brain. Brain Res. 110: 273-281, 1976. 13. Gebhart, G.F. and Spratt, J.L. Morphine-6-hemisuccinate as a narcotic analgesic. Life Sci. 18: 829, 1976. 14. Lewis, V.A. and Gebhart, G.F. Evaluation of the periaqueductal central gray (PAG) as a morphine specific locus of action and examination of morphine-induced and stimulation- produced analgesia at coincident PAG loci. Brain Res. 124: 283-303, 1977. 15. Tremmel, F., Morris, M.D. and Gebhart, G.F. The effects of forebrain norepinephrine depletion on two measures of response suppression. Brain Res. 126: 185-188, 1977. 16. Lewis, Vahn A. and Gebhart, G.F. Morphine-induced and stimulation-produced analgesias at co-incident periaqueductal central gray loci: Evaluation of analgesic congruence, tolerance and cross tolerance. Exp. Neurol. 57: 934-955, 1977. 17. Morris, M.D.
Load more

Recommended publications
  • Drug Abuse in Iowa Evolving Issues & Emerging Trends
    1 Drug Abuse in Iowa Evolving Issues & Emerging Trends Iowa Office of Drug Control Policy September 2016 2 Rapid Changes + Mixed Messages = ???s Evolving Risks involving Medicines, Synthetics, Marijuana, etc. • What’s new (what is it, what’s in it, what’s it’s effect)? • Does it heal or hurt (medicine or menace)? • Is it legal or illegal? • What do we tell children (or anyone else) about it? • How is it different now, compared to what I experienced? • What do we know about it & when will we know more? • What’s next? 3 Youth Substance Use 40-Year Trends Current Use (past 30 days) Among U.S. 12th Graders 80% 70% 60% 50% 40% Alcohol 30% Marijuana 20% 10% Cigarettes 0% Monitoring the Future, 1975-2015 4 Drugs of Choice: All Iowans Primary Substance of Choice by Iowans in Treatment 90% 80% 70% 60% Alcohol 50% 50% Marijuana 40% Meth Cocaine 30% 25.6% Heroin Other 20% 14.8% 10% 6.3% 1.7% 0% 1.6% IDPH, 2014 5 Iowa Youth Substance Abuse 6th, 8th and 11th Grade Users, Last 30-Days 25% 23% 20% Alcohol 15% 14% Tobacco 12% Other Drug 9% 10% 10% Rx OTC 6% Meth 5% 4% 4% 3% 3% 1% 0% 1% 2002 2005 2008 2010 2012 2014 Iowa Youth Survey, 2014 6 Iowa Drug-Related Traffic Fatalities Number Killed in 2014 Testing Positive for Illicit Drugs 16 15% of those killed in Iowa traffic fatalities 14 in 2014 tested positive for illicit drugs. 12 10 8 6 4 2 0 Marijuana Meth Rx Synthetic Opium Other Does not include alcohol-related fatalities.
    [Show full text]
  • Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors
    Physiol Rev 92: 1699–1775, 2012 doi:10.1152/physrev.00048.2010 SENSORY AND SIGNALING MECHANISMS OF BRADYKININ, EICOSANOIDS, PLATELET-ACTIVATING FACTOR, AND NITRIC OXIDE IN PERIPHERAL NOCICEPTORS Gábor Peth˝o and Peter W. Reeh Pharmacodynamics Unit, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, Pécs, Hungary; and Institute of Physiology and Pathophysiology, University of Erlangen/Nürnberg, Erlangen, Germany Peth˝o G, Reeh PW. Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors. Physiol Rev 92: 1699–1775, 2012; doi:10.1152/physrev.00048.2010.—Peripheral mediators can contribute to the development and maintenance of inflammatory and neuropathic pain and its concomitants (hyperalgesia and allodynia) via two mechanisms. Activation Lor excitation by these substances of nociceptive nerve endings or fibers implicates generation of action potentials which then travel to the central nervous system and may induce pain sensation. Sensitization of nociceptors refers to their increased responsiveness to either thermal, mechani- cal, or chemical stimuli that may be translated to corresponding hyperalgesias. This review aims to give an account of the excitatory and sensitizing actions of inflammatory mediators including bradykinin, prostaglandins, thromboxanes, leukotrienes, platelet-activating factor, and nitric oxide on nociceptive primary afferent neurons. Manifestations, receptor molecules, and intracellular signaling mechanisms
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]
  • 16.19.20 Nmac 1 Title 16 Occupational And
    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]
  • Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 P.M
    The Florida Board of Nursing Controlled Substances Formulary Committee Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 p.m. Doreen Cassarino, DNP, ARNP, FNP-BC, BC- ADM, FAANP - Chair Joe Baker, Jr. Executive Director Kathryn L Controlled Substances Formulary Committee Agenda July 14, 2016 @ 2:00 p.m. Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator For more information regarding board meetings please visit http://floridasnursing.gov/meeting-information/ Or contact: Florida Board of Nursing 4052 Bald Cypress Way, Bin # C-02 Tallahassee, FL 32399-3252 Direct Line: (850)245-4125/Direct Fax: (850)617-6450 Email: [email protected] Call to Order Roll Call Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator I. Review & Approve Minutes from June 29, 2016 Meeting II. Open Discussion A. Recommendations to the Board of Nursing for Rule Promulgation B. Reference Material 1.
    [Show full text]
  • PCP Oral Fluid
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology PHENCYCLIDINE (PCP) ORAL FLUID KIT ELISA KIT INSTRUCTIONS PRODUCT # 120419 & 120415 (RTU) FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Phenylcyclidine (PCP) in human oral fluid. This assay was designed to be compatible with the Neogen NeoSal™ Oral Fluid Collection Device. DESCRIPTION Neogen Corporation’s Phenylcyclidine (PCP) ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the drug-enzyme conjugate is added and the mixture is incubated for 45 minutes at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB).
    [Show full text]
  • Syntheses and Analytical Characterizations of N-Alkyl-Arylcyclohexylamines
    LJMU Research Online Wallach, J, Colestock, T, Cicali, B, Elliott, SP, Kavanagh, PV, Adejare, A, Dempster, NM and Brandt, SD Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. http://researchonline.ljmu.ac.uk/id/eprint/3240/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Wallach, J, Colestock, T, Cicali, B, Elliott, SP, Kavanagh, PV, Adejare, A, Dempster, NM and Brandt, SD (2015) Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. Drug Testing and Analysis. ISSN 1942-7611 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ Drug Testing and Analysis Syntheses and analyti cal characterizations of N -alkyl - arylcyclohexylamines Journal:For Drug Peer Testing and Analysis Review Manuscript ID: DTA-15-0185.R1 Wiley - Manuscript type: Research Article Date Submitted by the Author: n/a Complete List of Authors: Wallach, Jason; University of the Sciences, Department of Pharmaceutical Sciences Colestock, Tristan; University of the Sciences, Department of Pharmaceutical Sciences Cicali, Brian; University of the Sciences, Department of Pharmaceutical Sciences Elliott, Simon; ROAR Rorensics, Kavanagh, Pierce; School of Medicine, Trinity Centre for Health Sciences, St.
    [Show full text]
  • Model Scheduling New Novel Psychoactive Substances
    Model Scheduling New/Novel Psychoactive Substances Act September 2018 (original version published in 2014). This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2018. NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non- commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact Jon Woodruff at [email protected] or (703) 836-7496 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE 1 FOR MODEL STATE DRUG LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 12 Section IV – Substituted Cathinones 18 Section V – Substituted Phenethylamines 22 Section VI – N-benzyl Phenethylamine Compounds 24 Section VII – Substituted Tryptamines 27 Section VIII – Substituted Phenylcyclohexylamines 28 Section IX – Fentanyl Derivatives 37 Section X – Unclassified NPS © 2018. NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non- commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact Jon Woodruff at [email protected] or (703) 836-7496 with any questions about the Model Language.
    [Show full text]
  • 2021 SB 1738 by Senator Brodeur 9-01008B-21 20211738__ Page 1 of 34 CODING
    Florida Senate - 2021 SB 1738 By Senator Brodeur 9-01008B-21 20211738__ 1 A bill to be entitled 2 An act relating to controlled substances; amending s. 3 893.03, F.S.; excluding from Schedule I cannabis if it 4 is contained within a pharmaceutical product approved 5 by the United States Food and Drug Administration; 6 providing an effective date. 7 8 Be It Enacted by the Legislature of the State of Florida: 9 10 Section 1. Paragraph (c) of subsection (1) of section 11 893.03, Florida Statutes, is amended to read: 12 893.03 Standards and schedules.—The substances enumerated 13 in this section are controlled by this chapter. The controlled 14 substances listed or to be listed in Schedules I, II, III, IV, 15 and V are included by whatever official, common, usual, 16 chemical, trade name, or class designated. The provisions of 17 this section shall not be construed to include within any of the 18 schedules contained in this section any excluded drugs listed 19 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded 20 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical 21 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted 22 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt 23 Anabolic Steroid Products.” 24 (1) SCHEDULE I.—A substance in Schedule I has a high 25 potential for abuse and has no currently accepted medical use in 26 treatment in the United States and in its use under medical 27 supervision does not meet accepted safety standards.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information PCPr (hydrochloride) Item No. 9001362 CAS Registry No.: 1934-55-0 Formal Name: 1-phenyl-N-propyl-cyclohexanamine, NH monohydrochloride MF: C15H23N • HCl FW: 253.8 Purity: ≥98% Stability: ≥2 years at -20°C Supplied as: A crystalline solid • HCl Laboratory Procedures For long term storage, we suggest that PCPr (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. PCPr (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the PCPr (hydrochloride) in the solvent of choice. PCPr (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of PCPr (hydrochloride) in these solvents is approximately 11, 2, and 500 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of PCPr (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of PCPr (hydrochloride) in PBS, pH 7.2, is approximately 1.6 mg/ml. We do not recommend storing the aqueous solution for more than one day. PCPr is a phencyclidine (PCP)-derived compound which is the propyl analog of the psychoactive compound eticyclidine. It is a known drug of abuse.1 The physiological and pharmacological characteristics of this compound have been poorly studied. This product is intended for forensic and research applications.
    [Show full text]